Natera (NASDAQ:NTRA) CFO Sells $131,077.16 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 478 shares of Natera stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $274.22, for a total value of $131,077.16. Following the transaction, the chief financial officer owned 51,637 shares in the company, valued at $14,159,898.14. This trade represents a 0.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, August 3rd, Michael Burkes Brophy sold 317 shares of Natera stock. The stock was sold at an average price of $267.99, for a total value of $84,952.83.
• On Wednesday, July 29th, Michael Burkes Brophy sold 1,863 shares of Natera stock. The stock was sold at an average price of $249.38, for a total transaction of $464,594.94.
• On Tuesday, July 28th, Michael Burkes Brophy sold 2,419 shares of Natera stock. The stock was sold at an average price of $253.96, for a total transaction of $614,329.24.
• On Monday, July 27th, Michael Burkes Brophy sold 782 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $203,703.18.

Natera Stock Up 21.4%

Natera stock opened at $322.10 on Friday. The company has a 50 day moving average of $254.03 and a 200-day moving average of $223.79. Natera, Inc. has a twelve month low of $149.38 and a twelve month high of $323.01. The stock has a market capitalization of $46.13 billion, a PE ratio of -236.84 and a beta of 1.51.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.82%. The firm’s quarterly revenue was up 37.7% on a year-over-year basis. During the same period last year, the business posted ($0.74) earnings per share. Equities analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a report on Friday, July 17th. Piper Sandler reiterated an “overweight” rating and set a $249.00 price objective on shares of Natera in a report on Tuesday, May 12th. William Blair began coverage on Natera in a research report on Tuesday, April 14th. They issued an “outperform” rating on the stock. BTIG Research boosted their target price on Natera from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Friday. Finally, Morgan Stanley upped their price target on Natera from $250.00 to $310.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $299.65.

Hedge Funds Weigh In On Natera

Large investors have recently modified their holdings of the business. Trust Co. of Vermont acquired a new stake in shares of Natera in the second quarter valued at about $26,000. Elevation Wealth Partners LLC acquired a new position in Natera during the second quarter valued at approximately $30,000. Reflection Asset Management acquired a new position in Natera during the fourth quarter valued at approximately $29,000. Palladiem LLC bought a new position in Natera in the fourth quarter valued at approximately $31,000. Finally, Bank of Jackson Hole Trust grew its stake in Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 83 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Revenue significantly exceeded expectations. Natera generated $752.8 million in second-quarter revenue, up 37.7% year over year and well above the $661.2 million analyst consensus. Gross margin also improved to 64.5% from 63.4% a year earlier. Natera Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The quarterly loss narrowed. Natera reported a loss of $0.47 per share, compared with a $0.74-per-share loss in the prior-year quarter, and better than the $0.49 loss expected by analysts. The result suggests continued operating improvement despite the company remaining unprofitable. Natera Reports Q2 Loss and Beats Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2026 revenue outlook to approximately $2.9 billion, above the roughly $2.8 billion consensus estimate. The higher guidance points to sustained momentum across Natera’s reproductive health, oncology, and transplant-testing businesses.
• Positive Sentiment: JPMorgan raised its price target on NTRA from $315 to $360 and maintained an “overweight” rating, signaling that the bank sees additional upside after the earnings beat. Benzinga
• Positive Sentiment: Natera submitted its Signatera bladder-cancer test to Japan’s PMDA for approval as a companion diagnostic. Clearance could expand the company’s international oncology market and create another source of long-term growth. Natera Submits Signatera to Japan’s PMDA
• Neutral Sentiment: Several executives sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. Because the sales were relatively small compared with their remaining holdings and were not discretionary open-market disposals, they provide limited negative information.
• Negative Sentiment: Natera remains unprofitable, and its very high valuation leaves the shares vulnerable to profit-taking if growth slows or future results fail to exceed elevated expectations. Commentary identifying NTRA as entering a potential profit-taking zone highlights this near-term risk. IBD 50 Stock Natera Profit-Taking Zone

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.